nach oben

Erschienen in:

01.06.2018 | Research Article

Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model

verfasst von: Renata S. Fernandes, Juliana O. Silva, Samuel V. Mussi, Sávia C. A. Lopes, Elaine A. Leite, Geovanni D. Cassali, Valbert N. Cardoso, Danyelle M. Townsend, Patrick M. Colletti, Lucas A. M. Ferreira, Domenico Rubello, André L. B. de Barros

Erschienen in: Molecular Imaging and Biology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Nanotheranostic platforms, i.e., the combination of both therapeutic and diagnostic agents on a single platform, are emerging as an interesting tool for the personalized cancer medicine. Therefore, the aim of this work was to evaluate the in vivo properties of a Tc-99m-labeled nanostructured lipid carrier (NLC) formulation, co-loaded with doxorubicin (DOX) and docosahexaenoic acid (DHA), for theranostic applications.

Procedures

NLC-DHA-DOX were prepared busing the hot melting homogenization method using an emulsification-ultrasound and were radiolabeled with Tc-99m. Biodistribution studies, scintigraphic images, and antitumor activity were performed in 4T1 tumor-bearing mice.

Results

NCL was successfully radiolabeled with Tc-99m. Blood clearance showed a relatively long half-life, with blood levels decaying in a biphasic manner (T_1/2 α = 38.7 min; T_1/2 β = 516.5 min). The biodistribution profile and scintigraphic images showed higher tumor uptake compared to contralateral muscle in all time-points investigated. Antitumor activity studies showed a substantial tumor growth inhibition ratio for NLC-DHA-DOX formulation. In addition, the formulation showed more favorable toxicity profiles when compared to equivalent doses of free administered drugs, being able to reduce heart and liver damage.

Conclusions

Therefore, NLC-DHA-DOX formulation demonstrated feasibility in breast cancer treatment and diagnosis/monitoring, leading to a new possibility of a theranostic platform.

Nur mit Berechtigung zugänglich

Stewart BW, Wild CP (2014) World cancer report 2014 latest world cancer statistics. International Agency for Research on Cancer, Lyon

Livi L, Meattini I, de Cardillo CL et al (2009) Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis. Tumori 95:422–426CrossRefPubMed

Shi Y, Moon M, Dawood S et al (2011) Mechanisms and management of doxorubicin cardiotoxicity. Herz 36:296–305CrossRefPubMed

Primeau AJ, Rendon A, Hedley D et al (2005) The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 27:8782–8788CrossRef

Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454CrossRefPubMed

Carvalho C, Santos RX, Cardoso S et al (2009) Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267–3285CrossRefPubMed

Jassem J, Pieńkowski T, Płuzańska A et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707–1715CrossRefPubMed

Germain E, Chajès V, Cognault S et al (1998) Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 75:578–583CrossRefPubMed

Colas S, Mahéo K, Denis F et al (2006) Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. Clin Cancer Res 12:5879–5886CrossRefPubMed

10.

Siddiqui RA, Harvey KA, Xu Z et al (2011) Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. Biofactors 37:399–412CrossRefPubMed

11.

Mahéo K, Vibet S, Steghens JP et al (2005) Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 39:742–751CrossRefPubMed

12.

Hardman WE, Avula CP, Fernandes G, Cameron IL (2001) Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res 7:2041–2049PubMed

13.

Parhi P, Mohanty C, Sahoo SK (2012) Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 17:1044–1052CrossRefPubMed

14.

Mamot C, Drummond DC, Hong K et al (2003) Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Update 6:271–279CrossRef

15.

Muller RH, Mader K, Gohla D (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm 50:161–177CrossRefPubMed

16.

Mehnert W, Mader K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165–196CrossRefPubMed

17.

Janib SM, Moses AS, MacKay JA (2010) Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 62:1052–1063CrossRefPubMedPubMedCentral

18.

Jo SD, SH K, Won Y-Y et al (2016) Targeted nanotheranostics for future personalized medicine: recent progress in cancer therapy. Theranostics 6:1362–1377CrossRefPubMedPubMedCentral

19.

Choi KY, Liu G, Lee S, Chen X (2012) Theranosticnanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nano 4:330–342

20.

Xie J, Chen X (2010) Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 62:1064–1079CrossRefPubMedPubMedCentral

21.

Yang DJ, Kim C, Schechter NR et al (2003) Imaging with 99mTc-ECDG targeted at the multifunctional glucose system: feasibility studies with rodents. Radiology 226:465–473CrossRefPubMed

22.

Saha GB (2010) Radiopharmaceuticals and methods of radiolabeling. In: Fundamentals of nuclear pharmacy. Springer, New York, pp 83–113CrossRef

23.

Mussi SV, Sawant R, Perche F et al (2014) Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells. Pharm Res 8:1882–1890CrossRef

24.

Mussi SV, Silva RC, Oliveira MC et al (2013) New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 48:282–290CrossRefPubMed

25.

Fernandes RS, Silva JO, Lopes SCA et al (2016) Technetium-99m-labeled doxorubicin as an imaging probe for murine breast tumor (4T1 cell line) identification. Nucl Med Commun 37:307–312PubMed

26.

Thrall JH, Ziessman HA (2003) Medicina Nuclear, 2nd edn. Guanabara Koogan, Rio de Janeiro

27.

Souza CM, Carvalho LF, Vieira TS et al (2012) Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. Biomed Pharmacother 66:491–498CrossRef

28.

Li Y, Wang J, Wientjes MG, JL A (2012) Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 64:29–39CrossRefPubMed

29.

Maeda H, Wu J, Sawa J, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284CrossRefPubMed

30.

Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–135CrossRefPubMed

31.

Reddy LH, Sharma LK, Chuttani K et al (2005) Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton’s lymphoma tumor bearing mice. J Control Release 105:185–198CrossRef

32.

Beloqui A, Solinis MA, Delgado A et al (2013) Biodistribution of nnostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological fators. Eur J Pharm Biopharm 84:309–314CrossRefPubMed

33.

Torchilin V (2009) Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 71:431–444CrossRefPubMed

34.

Yuan F, Dellian M, Fukumura D et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756PubMed

35.

Leu AJ, Berk DA, Lymboussaki A et al (2000) Absence of functional lymphatics within murine sarcoma: molecular and functional evaluation. Cancer Res 60:4324–4327PubMed

36.

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:246–257CrossRef

37.

Munn II (2003) Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 8:396–403CrossRefPubMed

38.

Gosh K, Thodeti CK, Dudley AC et al (2008) Tumor-derived endothelial cells exhibit aberrant Rhon-mediated mechanosensing and abnormal angiogenesis in vitro. Proc Natl Acad Sci U S A 105:11305–11310CrossRef

39.

Mastria EM, Chen M, McDaniel JR (2015) Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. J Control Release 118:52–58CrossRef

40.

Sun L, Deng X, Yang X et al (2014) Co-delivery of doxorubicin and curcumin by polymeric micelles for improving antitumor efficacy on breast carcinoma. RSC Adv 4:46737–46750CrossRef

41.

Wang J, Ma W, Tu W (2015) Synergistically improved anti-tumor efficacy by co-delivery doxorubicin and curcumin polymeric micelles. Macromol Biosci 15:1252–1261CrossRefPubMed

42.

Guffy MM, North JA, Burns CP (1984) Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res 44:1863–1866PubMed

43.

Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–1272CrossRefPubMed

44.

Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26:57–64CrossRefPubMed

45.

O’Brien MER, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 26:440–449CrossRef

46.

Shuhendler AJ, Prasad P, Zhang RX et al (2014) Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmuno compromised breast tumor model. Mol Pharmaceutics 14:2659–2674CrossRef

Titel: Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model
verfasst von: Renata S. Fernandes
Juliana O. Silva
Samuel V. Mussi
Sávia C. A. Lopes
Elaine A. Leite
Geovanni D. Cassali
Valbert N. Cardoso
Danyelle M. Townsend
Patrick M. Colletti
Lucas A. M. Ferreira
Domenico Rubello
André L. B. de Barros
Publikationsdatum: 01.06.2018
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 3/2018
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-017-1133-3

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model

Abstract

Purpose

Procedures

Results

Conclusions

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Purpose

Procedures

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Upregulated Sphingosine 1-Phosphate Receptor 1 Expression in Human and Murine Atherosclerotic Plaques

Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase

MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding

Letter to the Editor re: Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration

PET Imaging with S-[11C]Methyl-L-Cysteine and L-[Methyl-11C]Methionine in Rat Models of Glioma, Glioma Radiotherapy, and Neuroinflammation

A Non-Peptidic S100A9 Specific Ligand for Optical Imaging of Phagocyte Activity In Vivo

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie